Thesis (M.A.)--Trinity Evangelical Divinity School, 2004. / Abstract. Includes bibliographical references (leaves 75-78).

Thesis (Ph. D.)--University of California, Santa Cruz, 1985. / Typescript. Includes bibliographical references (leaves [267]-275).

Thesis (M.A.)--Trinity Evangelical Divinity School, 2004. / Abstract. Includes bibliographical references (leaves 75-78).

Thesis (M.A.)--Florida State University, 2006. / Advisor: Andrew Epstein, Florida State University, College of Arts and Sciences, Dept. of English. Title and description from dissertation home page (viewed June 8, 2006). Document formatted into pages; contains vii, 51 pages. Includes bibliographical references.

Thesis (M.A.)--Eastern Illinois University, 1967. / Includes bibliographical references (leaves [164-172]).

Dissertation (PhD) Florida State University, 2005. / Advisor: André J. Thomas, Florida State University, College of Music. Title and description from dissertation home page (viewed 5-14-2007). Document formatted into pages; contains 187 pages. Includes biographical sketch. Includes musical examples. Includes bibliographical references.

GOMES NETO, Antero. Modelo experimental de tumor no pulmão com implante de células tumorais por via intrabrônquica : avaliação dos efeitos da talidomida, gefitinib e paclitaxe. 2006. 164 f. Tese (Doutorado em Cirurgia) - Universidade Federal do Ceará. Faculdade de Medicina, Fortaleza, 2010. / Submitted by denise santos (denise.santos@ufc.br) on 2014-03-14T16:07:25Z No. of bitstreams: 1 2006_tese_agomesneto.pdf: 6071120 bytes, checksum: 96d84eba70f3a6b3fae12b1700c5ff69 (MD5) / Approved for entry into archive by denise santos(denise.santos@ufc.br) on 2014-03-14T16:09:16Z (GMT) No. of bitstreams: 1 2006_tese_agomesneto.pdf: 6071120 bytes, checksum: 96d84eba70f3a6b3fae12b1700c5ff69 (MD5) / Made available in DSpace on 2014-03-14T16:09:16Z (GMT). No. of bitstreams: 1 2006_tese_agomesneto.pdf: 6071120 bytes, checksum: 96d84eba70f3a6b3fae12b1700c5ff69 (MD5) Previous issue date: 2006 / Lung cancer has been the main cause of death from cancer worldwide over the past decade in spite of the appearance of new chemotherapy drugs and targeted therapies. It is therefore necessary to clarify the molecular and biological changes involved in carcinogenesis and tumor growth and to develop experimental models for the study of the biology of lung tumors and the effects of antineoplastic drugs. The objective of the study was to develop a practical and easily reproducible lung tumor model using immunocompetent rats and to evaluate the activity of antineoplastic drugs. One hundred ninety-one female Wistar rats, with an average weight of 199±23g, were randomly assigned to one of three experimental groups. All animals were anesthetized intraperitonially (ip) with 2.5% tribromoetanol (1ml/100g live weight), tracheostomized and intubated with a polyethylene catheter (16G) guided intrabronchially (ib) to the bottom of the lung for inoculation with Walker 256 tumor cells. Group 1 (n=32) established the ib cell implant technique and the tumor take rate with inoculation of 105 to 5×105 cells. Group 2 (n=16) evaluated tumor volume on the fifth day of implant with 4×105 cells and correlated chest findings from high-resolution computerized tomography (HRCT) and necropsy. Group 3 (n=143) evaluated the effect of antineoplastic drugs and validated the model in two stages. Stage 1 (n=72) evaluated tumor volume on the fifth day of implant with 4×105 cells, divided into 5 groups: control (CG), 0.9% NaCl (1ml/gavage); celecoxib (Gclx), 15, 30 and 60mg/kg/day/gavage; thalidomide (Gtld), 45mg/kg/d/sc; gefitinib (Ggfb), 25mg/kg/day/gavage; and thalidomide + gefitinib (Gtld + gfb). Stage 2 (n=71) evaluted the survival of the animals divided into six groups: Gc, Gclx, Gtld, Ggfb, Gtld + gfb, and Gpcl (paclitaxel) 8mg/kg ip. The overal take rate for implants of 4×105 cells was 96% (149/155), specifically 90% in the first experimental group, 100% in the second and 96% in the third. Surgical mortality was 4.2% (8/191); 21 animals were excluded due to absence of tumor in the lung, death from infection (pulmonary abscess) and other causes not related to the tumor. In Group 2, measures obtained with HRCT and necropsy were similar (r=0, 953, p<0.0001). In the first stage of Group 3 no difference in tumor volume was observed between treated animals and controls; in the second stage median survival time was significantly extended in animals treated with TLD, GFB and PCL (13, 13 and 29 days, respectively) compared to controls (11 days) (Log Rank test: p<0.001). In conclusion, the present lung tumor model with intrabronchial tumor cell implantation was shown to be feasible and was associated with high tumor take rates, minor surgical mortality, simple execution and easy reproducibility. HRCT was found to be a highly accurate method of diagnosis, localization and tumor measurement. The model was efficient in the evaluation of the antitumoral activity of the antineoplastic drug paclitaxel, the antiangiogenic drug thalidomide, and the EGFR tyrosine kinase inhibitor gefitinib, making it a valid model for testing new drugs in lung cancer. / O câncer de pulmão tem sido, na última década, a principal causa de morte por câncer no mundo, apesar do surgimento de novos quimioterápicos e das terapias alvo-direcionadas. Por isso, faz-se necessário o entendimento das alterações moleculares e biológicas envolvidas nos processos de carcinogênese e crescimento tumoral, bem como o desenvolvimento de modelos experimentais adequados que permitam estudar o comportamento biológico dos tumores de pulmão e o efeito de drogas antineoplásicas. O objetivo desse estudo foi desenvolver um modelo de tumor no pulmão em ratos imunocompetentes de execução simples e fácil reprodutibilidade, e avaliar a atividade de drogas antitumorais. Cento e noventa e um ratos Wistar fêmeas, peso médio de 199±23g, foram distribuídos ao acaso em três etapas experimentais. Todos os animais foram anestesiados com tribromoetanol 2,5% (1 ml/100g de rato) intraperitonial (ip), traqueostomizados e intubados com cateter de polietileno 16G, seguindo-o por via intrabrônquica (ib) até as porções inferiores do pulmão para inocular células do tumor 256 de Walker. A 1a etapa (n=32) foi feita para estabelecer a técnica do implante de células por via ib e o índice de pega tumoral, inoculando-se de 105 a 5×105 células. A 2a etapa (n=16) para avaliar o volume tumoral no 5o dia do implante de 4×105 células e correlacionar os achados da tomografia computadorizada de alta resolução (TCAR) de tórax com os da necropsia. A 3a etapa (n=143) para a avaliar o efeito de drogas e validar o modelo, sendo dividida em duas fases. A 1a fase (n=72) para avaliar o volume tumoral no 5o ou 6o dia do implante de 4×105 células do tumor, composta de cinco grupos: Grupo controle (Gc), NaCl 0,9% (1ml/gavagem); Grupo celecoxib (Gclx), 15, 30 e 60 mg/kg/dia/gavagem; Grupo talidomida (Gtld), 45 mg/kg/d/sc; Grupo gefitinib (Ggfb), 25 mg/kg/dia; Grupo talidominda + gefititinib (Gtld +gfb). A 2a fase (n=71) para avaliar a sobrevida dos animais, com seis grupos: Gc, Gclx (15, 30, 60), Gtld, Ggfb, Gtld + gfb, Grupo paclitaxel (Gpcl), 8 mg/kg ip. O índice geral de pega do tumor com o implante 4×105 células foi de 96% (149/155), sendo 90% na 1a etapa, 100% na 2a etapa e 96% na 3a etapa. A mortalidade cirúrgica foi de 4,2% (8/191) e 21 animais foram excluídos do estudo por ausência de tumor no pulmão, morte por infecção (abscesso pulmonar) e outras causas não relacionadas com o tumor. Na 2a etapa, as medidas do tumor feitas na TCAR e comparadas com a necropsia foram semelhantes (r=0, 953, p<0,0001). Na 1a fase da 3a etapa, não se observou diferença no volume tumoral dos animais dos grupos tratados em relação ao controle; e na 2a fase verificou-se aumento significante da sobrevida mediana dos animais tratados com TLD, GFB e PCL (13, 13 e 29 dias, respectivamente), em relação ao controle (11dias), teste de Log Rank: p<0,001. Conclui-se que o modelo de tumor de pulmão por implantação de células tumorais por via intrabrônquica mostrou-se viável, com alto índice de pega e mortalidade cirúrgica desprezível, de execução simples e fácil reprodutibilidade. A TCAR revelou-se um método de imagem de alta acurácia no diagnóstico, localização e mensuração das lesões tumorais. O modelo mostrou-se eficaz na avaliação de atividade antitumoral de drogas antineoplásicas como o paclitaxel, antiangiogênicas como a talidomida, e inibidores de tirosina quinase do EGFR como o gefitinib.

Made available in DSpace on 2016-08-26T15:19:01Z (GMT). No. of bitstreams: 1 tese_6407_DISSERTACAO FINAL_CLERISTON BOECHAT.pdf: 275592712 bytes, checksum: bf7398cd8738a8c8dff1819f50ff0a4f (MD5) Previous issue date: 2013-04-02 / Investiga o estilo documentário do fotógrafo americano Walker Evans na exposição e no livro American Photographs, de 1938. Analisa as fotografias do autor a partir de textos críticos de diversos autores, dentre eles Walter Benjamin, Michel Foucault, Rosalind Krauss, John Szarkowski e Alan Trachtenberg. Identifica e aborda as principais influências literárias e fotográficas na construção do estilo documentário: o não-aparecimento do autor defendido por Gustave Flaubert; o espírito de modernidade de Charles Baudelaire; o repertório e a abordagem direta de Eugène Atget; a construção de uma tradição fotográfica americana em Mathew Brady e em Paul Strand. Ao tratar da exposição, aborda os principais temas desenvolvidos ali pelo artista e ainda como trabalhou a sequência fotográfica contra a ideia modernista da fotografia como imagem singular e contra a pompa da expografia museográfica. Aborda a relação entre o artista e o Museu de Arte Moderna de Nova York, o MoMA, instituição que patrocinou a publicação e abrigou a mostra. Ao tratar do livro American Photographs, aborda separadamente parte um e dois da publicação, ressaltando os diferentes temas e sequências desenvolvidos pelo artista. Palavras-chave: Fotografia. Walker Evans. Estilo documentário. American Photographs. MoMA.

In the laissez-faire system of the late nineteenth century, Sir Edmund Walker, Canadian businessman, saw his life in terms not of his personal gain, but of his service to his country. His Victorian curiosity and ethic of service prompted him to work for Canada in many varied areas from banking, to the arts, to planning a new imperial structure in the Round Table. By World War I, however, this Victorian ethic could no longer survive in the modern world which had evolved. Government also ended laissez-faire by entering fields which business philanthropy had neglected. While most Canadians seemed to recognize Sir Edmund's achievements, after the war they scoffed at his outdated views of service. Byron Edmund Walker, born in 1848 in Haldimand County, Ontario, was the eldest son of a poor, but educated, middle class, English family. Their love of culture and science was transmitted to him at an early age. Although he started banking at twelve, becoming president of the Canadian Bank of Commerce in 1907, Edmund Walker did not neglect this cultural heritage. The Champlain Society, Royal Ontario Museum, University of Toronto, National Gallery, Art Gallery of Ontario, and Guild of Civic Art in Toronto are some of the institutions which he worked for, or helped to found. During this same period Sir Edmund also built up the Canadian Bank of Commerce, the nation's second largest bank, and as the foremost banker in Canada, he led discussions at the decennial revision of the Bank Act. A self-made millionaire, Walker died in Toronto in 1924. Because his career coincided with Canada's greatest boom, from about 1900 to 1914, it is difficult to establish how much Sir Edmund's efforts actually contributed to his many accomplishments. This is further complicated by the fact that in these ventures he was assisted ably by Zebulon Lash, his enigmatic, corporation lawyer friend. Yet with qualifications, Walker's 'service' to Canada is still outstanding. This thesis, then, is primarily an examination of Sir Edmund Walker's ideas, and how they functioned in his Canadian environment. / Arts, Faculty of / History, Department of / Graduate

No description available.